RUTHERFORD, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company pioneering new technologies for diabetes management, has announced ethical approval for a long-term clinical study of its Continuous Blood Glucose Monitor (CBGM). The study, approved by the St. Vincent's Hospital Melbourne Human Research Ethics Committee, will involve up to 30 participants with type 1 and type 2 diabetes who require glucose monitoring and intensive insulin therapy. This single arm, multi-center study aims to evaluate the performance and safety of the CBGM over an initial one-year period, with potential extensions up to three years. The device is notable for its implantable nature, eliminating the need for on-body wearables, and directly measures blood glucose, potentially offering more accurate real-time glucose values. The first patient implants are expected by July, under the leadership of Principal Investigator Professor David O'Neal.